

MASTERCLASS



NVAF-Related Stroke Prevention in the UK: A Practical Perspective

29–30 March 2019 | The Crystal, London

This meeting will contain promotional content

This promotional meeting is organised and funded by the BMS/Pfizer Alliance



Bristol-Myers Squibb



The BMS/Pfizer Alliance is delighted to invite you to an **educational Masterclass on NVAF-related stroke prevention** in the UK; our expert faculty will discuss the practical use of NOACs and share advice on how to optimise your local AF service provision.

The meeting will take place on 29–30 March 2019 in the private venue The Crystal, London, and will be led by a highly experienced faculty of UK experts – chaired by Dr Derek Connolly (Consultant Cardiologist, Birmingham, UK). There will be extensive opportunities for interactivity throughout – particularly during the breakout sessions, which will include patient case studies and workshops on clinical practice change.

You will learn about:

- The current picture of NVAF-related stroke prevention in the UK
- The characteristics of NOACs, their evolving use and how to integrate them as standard-of-care to reduce NVAF-related stroke and DVT/PE-related events
- How to optimise your NVAF/VTE service provision through multi-disciplinary team working in the evolving UK primary care landscape
- What tools, resources and practical guidance are available to support you.

Please confirm your interest with your local BMS/Pfizer representative; once your place is confirmed, you will be provided with further details.

This promotional meeting is organised and funded by the BMS/Pfizer Alliance



PP-ELI-GBR-4537 December 2018

Agenda preview

Day 1 – Friday 29 March

09:00–09:30	Registration
09:30–10:00	Welcome – current picture of NVAF-related stroke prevention in the UK
10:00–11:00	Patients with NVAF and increased stroke risk – are NOACs the new SoC?
11:00–11:20	Coffee break
11:20–12:50	Interactive workshops
12:50–13:50	Lunch
13:50–14:45	Patients with VTE – how NOACs change the landscape
14:45–15:00	Working together to improve the AF management pathway
15:00–15:20	Coffee break
15:20–16:20	Working together to improve the AF management pathway (<i>continued</i>)
16:20–17:00	Closing debate

Day 2 – Saturday 30 March

08:30–09:20	Welcome back – practical guide to NOAC use
09:20–10:05	Interactive workshops
10:05–10:25	Coffee break
10:25–11:10	Interactive workshops (<i>continued</i>)
11:10–12:20	Changing perspectives on patient care
12:20–12:30	Chair's summary and close
12:30–13:30	Lunch

AF: atrial fibrillation; BMS: Bristol-Myers Squibb; DVT: deep vein thrombosis; NOAC: non-vitamin K antagonist oral anticoagulant; NVAF: non-valvular atrial fibrillation; PE: pulmonary embolism; SoC: standard of care; VTE: venous thromboembolism.

Please note, the agenda is subject to change. This meeting is organised and funded by the BMS/Pfizer Alliance. Please note that under the law and the ABPI Code of Practice, the BMS/Pfizer Alliance may only provide hospitality and/or promote its medicines to members of the healthcare professions and appropriate administrative staff. Therefore, no unqualified person (e.g. medical students, non-medical spouses, partners) may be invited to or attend BMS/Pfizer Alliance meetings.

This promotional meeting is organised and funded by the BMS/Pfizer Alliance



Your personal data shall be processed in accordance with the attached Pfizer EEA HCP PRIVACY NOTICE, which explains – among others – the disclosures of transfer of value. A summary of this privacy notice (available in its entirety at <https://privacycenter.pfizer.com/en/hcp>) is included here.

Data protection. HCP personal data are processed (1) under the control of the Pfizer group and with our service providers, with the appropriate safeguards; (2) to interact and engage with you; to operate our business to comply with our legal obligations, for statistical purposes or to meet our legitimate interests in maintaining our business; and (3) to provide you with marketing and promotional communications. In particular, we will make public disclosures of the transfers of value that you receive from any Pfizer company. This public disclosure serves multiple legitimate interests of society, including patients, health care systems, the pharmaceutical industry, and to you as an HCP by: instilling public confidence in the integrity and independence of HCPs; helping safeguard public health by promoting HCP accountability to patients for decisions about their treatment; and demonstrating a commitment to continual education of HCPs which helps provide better care to patients.

Your personal data are collected from you in any of your interactions with Pfizer and from data companies providing information services in the healthcare sector, publicly accessible sources of professional information, and joint marketing partners. If you wish to contact us or Pfizer's EU Data Protection Officer in order to be provided with more details on these privacy practices or to request to exercise any data protection rights you may have (including requests to object to our legitimate interests or to withdraw a consent, where applicable), please visit the EEA Pfizer HCP Privacy Notice at

<https://privacycenter.pfizer.com/en/hcp>.

EEA: European Economic Area; HCP: healthcare professional.

This promotional meeting is organised and funded by the BMS/Pfizer Alliance



PP-ELI-GBR-4537 December 2018